enzym
inhibit
molecular
target
structur
activ
relationship
b
r
c
emerg
diseas
dearth
effect
pharmacolog
agent
therapeut
front
constitut
major
threat
global
public
health
man
exist
consequ
creat
exig
search
new
drug
improv
clinic
util
mean
potenti
avail
one
end
accumul
empir
evid
support
molecular
target
therapi
plausibl
egress
bglucuronidas
bglu
e
lysosom
acid
hydrolas
respons
catalyt
deconjug
bdglucuronid
emerg
viabl
molecular
target
sever
therapeut
applic
enzym
activ
level
bodi
fluid
also
deem
potenti
biomark
diagnosi
patholog
condit
moreov
due
role
colon
carcinogenesi
certain
druginduc
doselimit
toxic
develop
potent
inhibitor
bglu
human
intestin
microbiota
arous
increas
attent
year
nevertheless
although
literatur
survey
reveal
natur
product
synthet
scaffold
potenti
inhibitor
enzym
found
clinic
util
albeit
moder
poor
pharmacokinet
profil
henc
review
present
compendium
exploit
present
millennium
direct
toward
inhibit
bglu
aim
proffer
platform
new
scaffold
model
improv
bglu
inhibitori
potenc
develop
new
therapeut
agent
consequenti
world
today
embattl
increas
pauciti
effect
therapeut
agent
regimen
mani
patholog
condit
well
menac
drug
resist
advers
effect
avail
drug
result
smooth
effici
clinic
practic
rigidli
stymi
global
public
health
social
secur
man
life
expect
serious
threaten
trickl
disquiet
edg
likewis
burden
develop
new
therapeut
agent
amelior
statu
quo
becom
heavier
stakehold
drug
research
regard
molecular
target
therapi
fast
becom
spearhead
search
new
drug
improv
therapeut
effect
amongst
mani
target
explor
glycosyl
hydrolas
gh
notabl
due
role
mani
import
biolog
process
princip
function
catalyt
cleav
glycosid
bond
glycan
therebi
elicit
differ
physiolog
respons
therefor
inhibitor
class
enzym
enjoy
intens
research
develop
owe
potenti
antivir
anticanc
antidiabet
agent
well
therapeut
agent
genet
disord
gh
classifi
use
differ
indic
exampl
base
substrat
specif
cleav
oor
sglycosid
group
ec
class
hydrolas
nglycosid
belong
ec
class
advanc
genom
scienc
also
enabl
classif
gh
famili
base
amino
acid
sequenc
similar
system
group
gh
famili
clan
given
improv
conserv
protein
fold
sequenc
accordingli
review
enzym
bglucuronidas
ec
classifi
gh
famili
gha
clan
bglucuronidas
bglu
mainli
lysosom
hydrolas
wide
distribut
mammalian
tissu
bodi
fluid
microbiota
significantli
retain
endoplasm
reticulum
enzym
also
found
plant
fish
insect
mollusc
specif
human
bglu
belong
gh
famili
kda
ellipsoid
homotetramer
glycoprotein
kda
monom
contain
amino
acid
residu
fig
monom
precursor
synthes
initi
membranebound
ribosom
suffer
ctermin
proteolyt
process
amino
acid
propeptid
en
rout
transport
lysosom
xray
crystallographi
protein
structur
reveal
dihedr
symmetri
tetram
two
ident
monom
asymmetr
unit
aris
disulphidelink
dimer
monom
contain
three
structur
domain
fig
first
domain
barrellik
structur
jelli
roll
motif
second
domain
exhibit
geometri
ident
immunoglobulin
constant
domain
third
ctermin
domain
form
tim
barrel
motif
ba
activ
site
human
bglu
fig
viz
catalyt
acid
proton
donor
catalyt
nucleophil
carbonium
ion
stabil
plausibl
role
unclear
catalyt
role
hous
third
domain
four
catalyt
centr
tetram
moreov
enzym
optim
activ
acid
correspond
lysosom
environ
thermal
stabl
c
although
hyperthermophil
variant
exist
media
bglu
encod
gu
gene
defici
aris
mutat
encod
gene
associ
atherosclerosi
lysosom
storag
diseas
e
sli
syndrom
mucopolysaccharidosi
type
vii
hand
bacteri
bglu
express
human
gut
microbiota
strain
escherichia
coli
show
sequenc
similar
human
bglu
also
bacteri
loop
contain
acid
residu
found
human
bglu
optim
activ
neutral
ph
activ
site
catalyt
residu
catalyt
acid
catalyt
nucleophil
consist
activ
lysosom
gh
bglu
deconjug
bdglucuronid
correspond
aglycon
bdglucuron
acid
via
n
reaction
configur
retain
mechan
fig
catalyt
mechan
conceiv
proceed
follow
catalyt
glutam
acid
residu
bacteri
ortholog
proton
exocycl
glycosid
oxygen
glucuronid
henc
releas
aglycon
via
put
oxocarbenium
ionlik
transit
state
backsid
nucleophil
attack
glutam
ion
bacteri
ortholog
e
catalyt
nucleophil
stabil
transit
state
result
glucuronyl
ester
intermedi
invert
configur
final
hydrolysi
invert
attack
water
molecul
anomer
centr
releas
form
bdglucuron
acid
concurr
overal
retent
substrat
configur
due
increas
express
bglu
necrot
area
bodi
fluid
patient
differ
form
cancer
breast
cervic
colon
lung
renal
carcinoma
leukaemia
compar
healthi
control
enzym
proffer
reliabl
biomark
tumour
diagnosi
clinic
therapi
assess
overexpress
also
potenti
diagnost
tool
diseas
state
urinari
tract
infect
hiv
diabet
neuropathi
rheumatoid
arthriti
vein
empir
data
updat
clinic
applic
bglu
disord
provid
brenda
databas
bglu
activ
also
har
prodrug
monotherapi
normal
bodi
system
drug
xenobiot
detoxifi
via
glucuronid
n
conjug
reaction
import
pathway
phase
ii
metabol
catalys
udp
glucuronosyltransferas
ugt
result
usual
less
activ
glucuronid
metabolit
readili
excret
renal
clearanc
due
increas
polar
sometim
via
biliari
clearanc
howev
elev
level
bglu
activ
revert
process
deglucuronid
hydrolys
phase
ii
metabolit
activ
form
fig
henc
glycosid
drug
give
glucuronid
enhanc
select
releas
activ
form
necrot
site
via
bglumedi
deglucuronid
thu
improv
drug
therapeut
potenti
bglu
postul
abil
increas
regul
cell
treg
also
appli
lowdos
immunotherapi
ldi
manag
allerg
diseas
lyme
diseas
chronic
condit
hydrolyt
activ
glucuronid
conjug
har
forens
analysi
assess
microbi
water
qualiti
nonetheless
enterobacteri
bglu
deconjug
drug
xenobiot
glucuronid
gastrointestin
gi
tract
implic
colon
genotox
certain
druginduceddoselimit
toxic
exampl
gi
toxic
anticanc
drug
irinotecan
enteropathi
nonsteroid
antiinflammatori
drug
nsaid
diclofenac
tissu
inflamm
hepatox
furthermor
bglu
deem
potenti
molecular
target
anticanc
chemotherapi
consid
role
tumour
growth
metastasi
neonat
jaundic
treatment
due
high
express
breast
milk
role
enterohepat
bilirubin
circul
hyperbilirubinemia
diabet
mellitu
manag
consequ
posit
correl
diseas
state
enzym
activ
level
well
associ
periodont
antiinflammatori
agent
develop
owe
proinflammatori
role
follow
signific
releas
degranul
mast
cell
neutrophil
expectedli
inhibit
bglu
markedli
allevi
patholog
condit
advers
effect
henc
improv
regimen
efficaci
base
forego
extrapol
develop
potent
specif
noncytotox
inhibitor
bglu
imper
improv
clinic
efficaci
therapeut
agent
effect
diseas
manag
bear
mind
physiolog
signific
human
bacteri
ortholog
glycosyl
hydrolas
howev
fate
inhibitor
rest
inhibit
constant
k
sinc
gh
gener
character
high
rate
enhanc
k
cat
k
uncat
fold
also
accumul
evid
suggest
depend
inhibitori
potenc
abil
mimic
highli
enzymestabil
transit
state
enzymat
reaction
k
z
en
rout
catalyt
product
consid
proven
encourag
potenti
enzym
inhibit
molecular
target
therapi
drug
develop
continu
exploit
exposit
thereon
herein
present
comprehens
review
research
undertak
present
millennium
direct
toward
develop
potent
inhibitor
bglu
either
natur
product
synthet
scaffold
apropo
discuss
differ
inhibitor
articl
first
highlight
potenti
bglu
activ
diagnost
tool
within
defin
period
howev
therapeut
applic
prodrug
monotherapi
enzym
replac
therapi
ert
cover
excel
treat
review
hitherto
search
extant
literatur
reveal
although
exist
plethora
scholarli
research
potenti
inhibitor
bglu
activ
review
articl
exclus
devot
subject
matter
aim
review
therefor
bring
light
bioactiv
framework
bestow
promis
bglu
inhibitori
potenc
princip
goal
intim
reader
key
structur
featur
review
molecul
crucial
inhibitori
activ
toxic
profil
establish
comprehens
relationship
exist
report
molecul
avail
safe
easi
use
consist
lessinvas
costeffect
tool
earli
diagnosi
diseas
apprais
therapeut
intervent
uttermost
import
clinic
medicin
sinc
diseas
state
accompani
elev
level
specif
enzym
diseas
milieu
tissu
plasma
bodi
fluid
quantif
enzym
activ
level
seen
reliabl
biomark
either
diseas
statu
sever
effect
suscept
exposur
moreov
substrat
specif
select
quantif
enzym
presenc
biomolecul
make
tool
choic
thereto
review
bglu
activ
biomark
physiolog
import
condit
herebi
present
togeth
concis
summari
tabl
periodont
diseas
group
inflammatori
disord
trigger
host
immun
respons
action
virul
subgingiv
plaqu
bacteria
biofilm
activ
releas
polymorphonuclear
leukocyt
macrophag
gingiv
crevic
lead
gingiv
e
inflamm
periodont
tissu
distort
periodont
histolog
revers
improv
oral
hygien
subsequ
tissu
destruct
alveolar
bone
resorpt
tooth
loss
left
unattend
ie
periodont
therefor
reliabl
tool
ascertain
diseas
statu
sever
risk
efficaci
administ
therapi
highli
desir
clinician
howev
convent
diagnosi
involv
measur
periodont
clinic
paramet
probe
depth
pd
clinic
attach
level
cal
gingiv
index
ggi
bleed
probe
bop
alveolar
bone
loss
abl
suffer
intrins
limit
defin
statu
patient
periodontium
time
examin
periodont
diseas
suscept
risk
thu
sinc
periodont
character
influx
inflammatori
mediat
correspond
enzym
gingiv
sulcu
quantif
neutrophilderiv
bglu
activ
gingiv
crevicular
fluid
gcf
gcf
outflow
oral
caviti
subsequ
less
invas
estim
bglu
activ
saliva
consid
reliabl
biomark
periodont
diseas
diagnosi
effect
relationship
salivari
bglu
activ
periodont
clinic
paramet
pd
cal
ggi
investig
subject
differ
stage
periodont
diseas
mean
pd
ggi
number
site
pd
mm
total
number
white
blood
cell
blood
neutrophil
monocyt
show
highli
signific
correl
enzym
activ
cal
weaker
correl
use
logist
regress
model
presenc
least
site
pd
mm
diseas
criterion
bglu
activ
show
promis
potenti
tool
periodont
diseas
screen
assess
therapeut
intervent
studi
also
observ
smoke
statu
insignific
enzym
activ
howev
similar
studi
pd
cal
lymphocyt
count
exhibit
posit
correl
salivari
enzym
activ
signific
relationship
observ
ggi
recent
subject
chronic
gener
periodont
also
found
signific
increas
bglu
activ
compar
normal
one
although
reduct
enzym
activ
persist
smoker
regardless
periodont
statu
tabl
report
potenti
applic
bglu
activ
biomark
ach
activ
chronic
exposur
w
acut
exposur
n
elev
subject
chronic
acut
exposur
respect
ns
specifi
w
weak
correl
n
correl
pi
russel
periodont
index
threshold
distinguish
cultur
posit
cultur
neg
balf
acut
exposur
chronic
exposur
efficaci
therapeut
intervent
use
amoxicillin
metronidazol
downregul
amplifi
neutrophil
activ
studi
patient
aggress
periodont
treatment
involv
seven
consecut
day
antibiot
administr
concurr
scale
root
plan
surgic
therapi
total
month
posttreat
evalu
period
subsequ
markedli
downregul
neutrophil
activ
approxim
inhibit
bglu
activ
gcf
observ
periodont
health
also
restor
maintain
posttreat
evalu
anoth
studi
bglu
activ
posit
better
biomark
compar
alkalin
phosphatas
evalu
respons
nonsurg
periodont
therapi
patient
differ
stage
periodont
diseas
taken
togeth
result
articul
potenti
bglu
activ
indic
pd
tissu
inflamm
destruct
well
biomark
neutrophil
influx
diseas
risk
suscept
statu
sever
time
diagnosi
inflammatori
disord
howev
administr
doxycyclin
hyclat
subject
aggress
periodont
ineffici
salivari
bglu
activ
surprisingli
increas
enzym
activ
found
even
month
treatment
patient
decreas
although
author
conclud
bglu
concentr
facilit
detect
periodont
inflamm
worthi
biomark
suscept
contrast
result
linkabl
periodont
pretreat
subject
prior
examin
short
treatment
time
use
doxycyclin
empir
evid
affirm
role
inflammatori
mediat
signal
pathway
pathogenesi
insulin
resist
bcell
dysfunct
diabet
mellitu
parallel
inflammatori
mediat
eg
cytokin
mmp
also
produc
periodont
tissu
henc
lead
compromis
glycaem
control
access
system
circul
suscept
periodont
therefor
heighten
person
diabet
histori
hormon
imbal
vice
versa
put
effect
therapi
one
afford
improv
manag
accordingli
bglu
activ
found
significantli
elev
saliva
patient
chronic
periodont
diabet
compar
nondiabet
one
signific
correl
bglu
activ
observ
pd
cal
ggi
nondiabet
subject
periodont
wherea
periodont
paramet
similar
diabet
increas
diseas
burden
also
establish
bglu
activ
measur
sera
patient
diabet
periodont
compar
control
enzym
activ
higher
diabet
subject
periodont
higher
diabet
subject
without
periodont
differ
attribut
damag
lysosom
membran
consequ
enzym
leakag
cytosol
quantif
bglu
activ
neutrophil
leukocyt
expos
bacteria
stimuli
shown
diabet
patient
chronic
periodont
strikingli
higher
enzym
activ
compar
nondiabet
burden
periodont
healthi
subject
use
discrimin
analysi
studi
establish
bglu
activ
diagnost
potenti
great
accuraci
distinguish
healthi
subject
diseas
one
bglu
activ
stimul
nonopson
staphylococcu
aureu
show
strongest
correl
intens
periodont
paramet
compar
opson
zymosan
prodigiosan
highest
enzym
activ
stimul
opson
prodigiosan
strength
associ
salivari
bglu
activ
periodont
type
diabet
mellitu
examin
dentat
patient
differ
stage
periodont
diseas
diabet
patient
edentul
patient
subject
diabet
statu
contribut
significantli
bglu
activ
periodont
statu
greater
influenc
enzym
activ
higher
enzym
activ
also
found
nondiabet
dentat
patient
periodont
compar
edentul
control
overal
compar
bglu
activ
level
reliabl
biomark
diseas
sever
periodont
presenc
diabet
predat
studi
gcf
bglu
activ
also
correl
strongli
pd
cal
bop
regardless
diabet
statu
lower
enzym
activ
seen
diabet
subject
compar
periodont
result
suggest
lower
releas
bglu
respons
system
inflamm
diabet
due
reduc
defici
neutrophil
activ
contrast
amplifi
activ
respons
local
inflamm
periodont
despit
landmark
develop
oncolog
high
rate
morbid
mortal
increas
medic
cost
associ
form
cancer
coupl
patient
psycholog
trauma
diseas
diagnosi
remain
major
threat
global
public
health
success
diseas
manag
sustain
wellb
affect
individu
howev
subject
earli
diseas
diagnosi
constant
evalu
administ
therapi
turn
reli
effici
tumour
marker
ascertain
diseas
risk
statu
ie
earli
stage
metastat
cancer
although
vast
number
biomark
identifi
cancer
diagnosi
gain
clinic
approv
due
inconsist
fals
posit
util
success
biomark
specif
select
also
predict
treatment
respons
differenti
letharg
aggress
tumour
aetiolog
cancer
known
close
associ
inflammatori
pathway
oxid
stress
jointli
creat
microenviron
favour
neoplasia
henc
tumour
milieu
increas
extracellular
activ
lysosom
exoglycosidas
respons
catalyt
degrad
glycoconjug
occur
due
malignancymedi
celldeath
andor
lysosom
damag
vein
avail
practic
data
support
overexpress
bglu
extracellular
fluid
tissu
around
tumour
site
prime
factor
cancer
aetiolog
thu
suggest
enzym
viabil
cancer
biomark
exampl
bglu
activ
higher
blood
sampl
patient
colorect
adenocarcinoma
compar
healthi
control
base
cell
matur
clinic
grade
enzym
activ
highest
subject
low
moder
differenti
cell
subject
tumour
infiltr
surround
tissu
organ
viscer
peritoneum
respect
estim
serum
bglu
activ
case
prove
sensit
specif
distinguish
diseas
healthi
subject
likewis
enzym
activ
elev
periton
fluid
patient
ovarian
endometri
cancer
compar
women
infertil
use
control
stronger
correl
cancer
stage
bglu
activ
bgalactosidas
amannosidas
reiter
improv
clinic
viabil
bglu
activ
biomark
gynaecolog
tumour
statu
sever
howev
bglu
activ
equal
elev
periton
fluid
patient
pelvic
inflamm
henc
compromis
applic
differenti
diagnosi
gynaecolog
cancer
pelvic
inflammatori
diseas
bacteri
periton
lifethreaten
inflamm
peritoneum
e
tissu
line
inner
abdomin
wall
inflammatori
condit
cellular
damag
polymorphonuclear
leukocyt
activ
increas
level
lysosom
enzym
extracellular
space
via
enzym
leakag
cellular
membran
thu
quantif
enzym
provid
potenti
diagnost
platform
fact
bglu
activ
periton
fluid
patient
cultur
posit
bacteri
periton
greater
compar
patient
acut
mesenter
lymphaden
control
respect
periton
fluidbglu
activ
measur
case
hold
greater
clinic
potenti
compar
bgalactosidas
amannosidas
earli
diseas
diagnosi
evalu
patient
respons
treatment
similarli
consid
current
global
preval
antimicrobi
resist
time
diagnosi
bacteriamedi
mening
inflamm
bacteri
mening
crucial
outcom
therapeut
intervent
shown
bglu
activ
elev
cellfre
cerebrospin
fluid
csf
bacteri
mening
patient
earli
diseas
pathogenesi
even
tradit
laboratori
paramet
number
csf
cell
csfblood
glucos
ratio
protein
concentr
indic
normal
statu
csfbglu
biomark
superior
tradit
paramet
earli
sensit
predict
patient
respons
antibiot
treatment
csfbglu
activ
neonat
infant
also
studi
biomark
differenti
diagnosi
steril
csf
pleocytosi
due
urinari
tract
infect
uti
mening
median
bglu
activ
csf
patient
show
signific
differ
without
overlap
diseas
state
ie
bacteri
mening
viral
mening
uti
steril
csf
pleocytosi
median
enzym
activ
lowest
febril
subject
without
csf
pleocytosi
use
control
proffer
unambigu
diagnosi
condit
sensit
specif
contrast
broad
overlap
found
classic
csf
laboratori
paramet
viz
csf
cell
number
neutrophil
number
protein
concentr
csfblood
glucos
ratio
recent
casecontrol
studi
conclud
bglu
activ
bronchoalveolar
lavag
fluid
balf
clinic
use
biomark
bacteri
lung
infect
balf
sampl
children
enzym
activ
significantli
higher
patient
posit
balf
bacteri
cultur
compar
cultur
neg
balf
ce
nmol
mlh
identifi
optimum
activ
valu
allow
differenti
sampl
screen
ie
ce
sensit
specif
moreov
receiv
oper
characterist
roc
curv
analysi
establish
superior
higher
prognost
valu
bglu
activ
bacteri
lung
infect
compar
polymorphonuclear
cell
count
human
leukocyt
elastas
tnfa
repeat
exposur
organophosphoru
compound
op
pesticid
respons
lethal
poison
seen
agricultur
veterinari
worker
particularli
develop
countri
op
exert
fatal
effect
inhibit
acetylcholinesteras
ach
nervou
tissu
lead
muscarin
nicotin
effect
central
nervou
disturb
hand
bglu
retain
liver
microsom
endoplasm
reticulum
form
noncoval
bind
complex
accessori
kda
glycoprotein
egasyn
carboxylesteras
isozym
liver
intak
op
howev
cleav
microsom
bgluegasyn
complex
thu
elev
level
bglu
plasma
consequ
make
altern
biomark
op
pesticid
poison
diagnosi
crosssect
studi
pest
control
worker
plastic
greenhous
worker
establish
plasma
bglu
activ
sensit
biomark
op
poison
compar
butyrylcholinesteras
buch
acid
phosphatas
acp
enzym
activ
higher
subject
increas
exposur
low
exposur
control
bglu
activ
correl
significantli
buch
acp
activ
likewis
casecontrol
studi
serum
bglu
activ
significantli
increas
patient
sever
poison
compar
mildli
affect
patient
control
differ
enzym
activ
latter
group
insignific
nonetheless
mildli
expos
subject
report
show
elev
bglu
activ
sever
expos
control
subject
suggest
enzym
util
diagnos
lowlevel
op
exposur
instanc
studi
observ
order
serum
bglu
activ
base
poison
sever
mild
sever
moder
poison
order
h
admiss
mild
sever
z
moder
poison
strong
correl
also
persist
serum
bglu
buch
activ
similar
result
also
obtain
recent
crosssect
studi
therein
moder
expos
subject
show
higher
enzym
activ
highli
expos
nonsignific
statist
differ
persist
control
highli
expos
group
notabl
bglu
activ
correl
well
diabet
propens
lipid
profil
liver
function
buch
ach
anoth
crosssect
studi
signific
differ
plasma
bglu
activ
exist
control
subject
chronic
exposur
year
op
activ
level
similar
control
patient
acut
poison
although
examin
acut
poison
patient
show
increas
level
plasma
bglu
activ
howev
case
report
acut
op
selfpoison
patient
reach
contrast
conclus
oppos
result
link
sampl
size
limit
data
patient
medic
histori
moreov
reduc
suscept
bgluegasyn
complex
op
human
anoth
primal
factor
contrast
murin
bgluegasyn
interact
bind
human
independ
ctermin
amino
acid
propeptid
bglu
esteras
activ
site
egasyn
rather
involv
amino
residu
bglu
intern
segment
ie
residu
progress
moment
achiev
drug
discoveri
isol
wealth
chemic
entiti
ie
natur
product
gift
man
natur
mani
success
molecular
candid
pharmaceut
drug
discoveri
programm
indebt
presenc
natur
productderivedinspir
fragment
scaffold
therefor
chemic
space
natur
product
plant
microb
continu
muchresearch
depositori
therapeut
signific
molecul
section
review
applic
natur
product
includ
isol
compound
whole
plant
extract
natur
productinspir
molecul
potent
inhibitor
bglu
structur
select
inhibitor
ic
mm
present
tabl
end
section
clarif
dsacchar
fig
saccharolacton
dglucar
activ
nontox
bglu
inhibitor
respons
strong
inhibitori
potenc
found
sacchar
solut
precipit
increas
interest
compound
despit
poor
stabil
physiolog
ph
dsacchar
dsal
explor
extens
therapeut
signific
although
ic
valu
mm
report
pioneer
work
valu
ca
mm
recurr
literatur
nevertheless
concentr
mm
dsal
complet
inhibit
hydrolyt
action
human
liverderiv
bglu
quercetin
glucuronid
inhibit
bglu
breast
milk
record
mm
also
use
urin
sampl
male
spraguedawley
rat
dsal
identifi
via
metabolom
strategi
one
therapeut
constitu
liuweidihuang
pill
famou
tradit
chines
prescript
cancer
treatment
prevent
wherea
cumul
studi
intraperiton
pre
cotreat
femal
wistar
rat
mgml
mgml
ml
dsal
reduc
sever
induc
smallintestin
mucos
damag
assess
number
apoptot
cell
mitot
figur
compar
treat
control
damag
reduct
independ
treatment
schedul
synthet
natur
precursor
dsal
ie
dsdl
fig
dglucuronoglacton
dgl
respect
also
potent
inhibit
bglu
activ
male
fischer
rat
therebi
provid
chemoprevent
effect
azoxymethaneinduc
colon
carcinogenesi
diet
supplement
dsdl
week
significantli
reduc
aberr
crypt
foci
format
ie
preneoplast
lesion
respect
compar
tabl
activ
natur
productderiv
bglu
inhibitor
ic
azoxymethanecontrol
dgl
afford
signific
reduct
colon
tumour
incid
initi
phase
addit
week
treatment
dsdl
high
dose
dgl
subcutan
inject
mgkg
azoxymethan
provid
inhibit
colon
carcinogenesi
postiniti
phase
suggest
dsdl
block
agent
may
inhibit
preneoplasia
initi
phase
dgl
activ
postiniti
colon
carcinogenesi
increas
hydrolyt
stabil
dsdl
dsal
vivo
might
also
respons
observ
phenomena
anoth
studi
dsal
therapeut
effici
compar
natur
precursor
dgl
reduc
epiderm
hyperplasia
letharg
tumour
promot
inflamm
anthracen
dmba
induc
complet
skin
carcinogenesi
sencar
mice
pre
cotreat
murin
model
dsal
twice
weekli
topic
administr
mg
dietari
treatment
significantli
reduc
epiderm
hyperplasia
inflamm
dmbacontrol
dosedepend
manner
dsal
also
inhibit
initi
carcinogenesi
reduc
dmbainduc
oxid
dna
damag
hydroxyl
guanin
mutat
codon
hara
gene
contrast
dgl
inhibit
epiderm
hyperplasia
topic
treatment
inflamm
dietari
treatment
diet
albeit
inferior
potenc
compar
dsal
interestingli
anoth
lactonebas
bglu
inhibitor
fig
exhibit
superior
potenc
compar
dsal
isol
ethyl
acet
extract
aspergillu
terreu
endophyt
fungu
initi
isol
marin
alga
laurencia
ceylanica
butyrolacton
ic
mm
possess
stronger
potenc
prenyl
isom
bglu
breast
milk
believ
involv
neonat
jaundic
hyperbilirubinemia
increas
serum
bilirubin
level
via
enterohepat
bilirubin
circul
breastf
newborn
contrast
fed
infant
formula
therefor
suppress
bglumedi
deglucuronid
proffer
practic
regimen
laspart
acid
fig
casein
hydrolys
formula
identifi
activ
bglu
inhibitor
respons
lower
level
neonat
jaundic
observ
newborn
receiv
formula
mm
natur
amino
acid
inhibit
bglu
potent
disom
moreov
random
doubleblind
clinic
trial
involv
supplement
breastfeed
first
week
life
dose
laspart
acid
ml
waterday
potent
bglu
activ
higher
concentr
enzymat
hydrolys
casein
infant
formula
contain
inhibitor
wheycasein
routin
formula
lack
inhibitor
laspart
acid
supplement
minim
aliquot
concentr
significantli
lower
transcutan
bilirubin
level
lower
control
lead
higher
faecal
bilirubin
excret
reduc
neonat
jaundic
advers
effect
flavonoid
evid
indispens
class
natur
product
due
ubiqu
veget
domain
therapeut
signific
found
varieti
plant
part
leav
flower
stem
nut
seed
etc
perform
import
function
especi
plant
growth
protect
pathogen
invas
intrins
properti
encourag
util
major
constitu
differ
local
medicin
formul
diet
accept
toxic
profil
physiolog
toler
present
druggabl
subject
flavonoid
typifi
ring
system
basic
structur
skeleton
consist
two
benzen
ring
b
link
heterocycl
pyran
ring
c
fig
variat
chroman
core
ring
c
attach
posit
ring
b
due
biosynthet
origin
lead
classif
flavon
flavanol
flavanon
flavonol
isoflavon
neoflavonoid
anthocyanin
chalcon
ring
system
presenc
hydroxyl
unit
avail
flavonoid
differ
pharmacolog
properti
antidiabet
antioxid
antimicrobi
antiplasmodi
antiprolif
particularli
enzym
inhibit
luteolin
fig
dietari
report
viabl
chemoprevent
anticarcinogen
agent
plausibl
inhibit
bacteri
bglumedi
enterohepat
circul
colon
carcinogen
cumul
studi
use
male
wister
rat
show
pre
cotreat
luteolin
intragastr
gavag
per
os
po
mgkg
bodi
weightday
significantli
reduc
bacteri
bglu
activ
therebi
suppress
dmh
induc
colon
adenocarcinoma
dosedepend
manner
compar
dmhcontrol
although
mg
kg
day
produc
similar
result
luteolin
supplement
also
reduc
tumour
size
cm
cm
initi
postiniti
stage
respect
well
reduct
tumour
incid
addit
luteolin
catechin
identifi
key
constitu
leaf
extract
pistacia
terebinthu
respons
high
e
coli
bglu
inhibitori
potenc
highest
test
concentr
mgml
leaf
extract
exhibit
inhibit
bglu
activ
correspond
ic
valu
mgml
anoth
exploit
natur
flavonoid
evalu
inhibitori
strength
e
coli
bglu
establish
luteolin
similar
flavon
e
baicalein
scutellarein
glucuronid
analogu
scutellarin
well
dietari
ubiquit
occur
flavonol
e
quercetin
superior
inhibitor
ic
mm
compar
refer
inhibitor
dsal
ic
mm
isoflavon
dihydroflavon
display
weaker
inhibit
overal
luteolin
scutellarein
emerg
potent
flavonebas
e
coli
bglu
inhibitor
ic
mm
respect
sar
analysi
fig
reveal
import
pyrogallol
unit
bacteri
bglu
inhibit
unsubstitut
replac
hydroxi
unit
methoxi
glycosyl
unit
led
signific
loss
inhibitori
activ
omethyl
instal
oh
unit
also
detriment
potenc
wherea
presenc
hydroxi
unit
favour
potenc
addit
molecular
dock
studi
luteolin
scutellarein
activ
site
e
coli
bglu
show
hydrogen
bond
hb
interact
phenol
oh
unit
catalyt
acid
well
hydrophob
contact
bacteri
loop
furthermor
subject
methanol
extract
edibl
flower
pedicel
aquat
rhizomat
herb
e
nymphaea
pubescen
water
lili
bioactivityguid
fraction
establish
superior
bacteri
bglu
inhibitori
potenc
crude
flower
extract
compar
pedicel
extract
silymarin
e
market
natur
bglu
inhibitor
kaempferol
subsequ
identifi
one
activ
metabolit
promis
activ
ic
mm
superior
silymarin
interestingli
lower
activ
kaempferol
compar
flavonoid
affirm
sar
result
describ
earlier
amidst
constitu
found
commonli
use
chines
herbal
medicin
two
prenylflavonoid
sanggenon
c
fig
kuwanon
g
emerg
potent
broadspectrum
inhibitor
inhibit
ic
mm
respect
whole
human
gut
bacteri
bglu
consist
eight
bacteri
isol
compar
refer
compound
amoxapin
inhibit
compound
exhibit
improv
potenc
recombin
bglu
e
coli
ecogu
pasteuri
spasgu
ic
mm
respect
compar
compound
ic
mm
respect
howev
compound
stronger
inhibitor
bglu
three
repres
bacteri
isol
e
coli
e
fergusonni
pasteuri
compar
compound
addit
molecular
dock
studi
bind
pocket
ecogu
spasgu
reveal
flavonoid
bind
via
hydroxi
group
alloster
site
activ
site
recombin
enzym
higher
number
hb
interact
form
compound
support
overal
increas
potenc
compar
compound
realiz
proinflammatori
mediat
bglu
releas
degranul
mast
cell
neutrophil
play
signific
role
inflammatori
disord
spark
increas
interest
search
potent
inhibitor
process
antiinflammatori
drug
candid
regard
dihydroxychalcon
fig
isol
root
hypericum
geminiflorum
hold
therapeut
promis
compound
potent
inhibit
releas
bglu
degranul
rat
neutrophil
ic
valu
mm
respect
better
refer
inhibitor
trifluoperazin
howev
compound
show
moder
activ
enzym
releas
degranul
rat
periton
mast
cell
ic
mm
convers
isom
luteolin
e
norartocarpetin
fig
flavonoidlik
mornigrol
fig
isol
bark
moru
nigra
black
mulberri
moder
potent
bglu
inhibitor
mm
compound
show
inhibit
respect
releas
bglu
activ
rat
neutrophil
howev
chiral
flavonoid
alkaloid
isol
ethanol
extract
scutellaria
moniliorrhiza
subsequ
separ
use
chiral
hplc
e
scumonilin
fig
better
drug
candid
compar
compound
similar
compound
scumonilin
inhibit
mm
bglu
releas
activ
rat
neutrophil
ic
valu
mm
respect
better
refer
inhibitor
ginkgolid
b
ic
mm
compound
also
potent
lead
molecul
compar
glucuron
ester
fig
isol
similar
scutellaria
regeliana
chiral
egeninebas
alkaloid
isol
rhizom
corydali
decumben
compound
show
inhibit
mm
wherea
compound
inferior
inhibitor
concentr
inhibit
evid
due
phycocyaninrich
content
potent
reduct
zymosaninduc
damag
knee
joint
histolog
architectur
edibl
bluegreen
microalga
e
spirulina
deem
therapeut
viabl
antiarthrit
agent
analysi
synovi
fluid
femal
mice
knee
joint
intraarticular
inject
zymosan
follow
oral
administr
spirulina
watersuspens
mgkg
mgkg
show
inhibit
bglu
activ
respect
subsequ
arthrit
paramet
tibial
articular
cartilag
destruct
eros
bone
structur
articular
tissu
inflamm
loss
gener
joint
architectur
pannu
format
markedli
reduc
spirulina
fed
mice
compar
receiv
zymosan
antiinflammatori
antiarthrit
effect
compar
refer
drug
triamcinolon
tuber
extract
arisaema
tortuosum
whipcord
cobra
lili
shown
moder
antiinflammatori
effect
via
bglu
inhibit
dosedepend
manner
conceiv
presenc
quercetin
rutin
lectin
identifi
chromatograph
profil
facilit
maximum
inhibit
mgml
superior
refer
inhibitor
salicyl
acid
employ
similar
approach
ginger
rhizom
fig
identifi
inhibit
bglu
mm
compar
salicyl
acid
inhibit
also
noteworthi
constitu
profil
essenti
oil
extract
leav
seven
local
varieti
piper
betl
l
identifi
eugenol
ic
valu
mgml
similar
mgml
silymarin
although
essenti
oil
moder
bglu
inhibitor
ic
mgml
howev
metabolom
profil
leafi
shootsmethanol
extract
three
swertia
speci
viz
chirayita
decussata
bimacul
present
chirayita
strongest
inhibitor
bglu
xanthon
activ
metabolit
respons
swertia
speci
potenc
norathyriol
mangiferin
emerg
activ
therapeut
promis
xanthon
ic
mm
potent
silymarin
shikunshitokamiho
sktk
tradit
orient
formul
fenugreek
seed
fg
indian
spice
natur
ethnotherapeut
agent
potenti
ident
luteolin
ie
attenu
colon
carcinogenesi
via
potent
inhibit
bacteri
bglu
activ
oral
administr
spf
male
icr
mice
diet
supplement
mgkg
mgkg
sktk
water
extract
week
subcutan
inject
dmh
weekli
equipot
reduc
bglu
activ
treatment
control
dmh
alon
respect
tumour
incid
colon
measur
number
aberr
crypt
foci
also
significantli
reduc
distribut
sigmoid
descend
colon
control
distribut
rectum
mgkg
mgkg
dose
respect
similarli
diet
supplement
fg
significantli
reduc
intestin
bglu
activ
lead
mark
reduct
tumour
incid
male
wister
rat
receiv
dmh
alon
week
rat
receiv
dmh
gkg
fg
water
extract
cumul
period
flavonoid
saponin
fibr
rich
content
fg
presum
respons
anticarcinogen
activ
hepatoprotect
activ
chines
medicin
formul
e
reduohanxiaotang
use
treatment
stroke
liver
diseas
also
attribut
abil
inhibit
bacteri
bglu
activ
vivo
water
extract
local
formul
two
ingredi
viz
rhizom
pueraria
thunbergiana
scutellaria
baicalensi
potent
inhibit
activ
e
coli
rat
liverderiv
bglu
ic
valu
rang
mgml
subsequ
oral
administr
extract
mgkg
allevi
ccl
induc
liver
injuri
measur
signific
reduct
serum
aspart
aminotransferas
ast
alanin
aminotransferas
alt
lactic
acid
dehydrogenas
ldh
level
compar
control
superior
hepatoprotect
effect
pueraria
thunbergiana
accredit
isoflavon
daidzein
fig
aglycon
metabolit
main
compon
puerarin
daidzin
intestin
bacteria
daidzein
inhibit
e
coli
rat
liver
bglu
ic
mgml
respect
wherea
puerarin
daidzin
inact
fascinatingli
structur
similar
tectorigenin
aglycon
metabolit
e
tectoridin
isol
flower
pueraria
thunbergiana
exhibit
better
inhibitori
potenc
ic
mgml
congen
mgkg
intraperiton
pretreat
male
icr
mice
tectorigenin
mgkg
oral
administr
tectoridin
provid
better
hepatoprotect
dimethyl
diphenyl
bicarboxyl
ddb
daidzein
significantli
lower
serum
ast
alt
ldh
level
rel
ccl
treat
control
prodrug
behaviour
tectoridin
ident
puerarin
daidzin
also
establish
absenc
serum
mgkg
oral
administr
tectorigenin
detect
failur
provid
desir
hepatoprotect
mgkg
intraperiton
administr
triterpenoid
acid
fig
also
known
enoxolon
aglycon
metabolit
human
intestin
bacteria
respons
hepatoprotect
activ
exhibit
saponin
e
glycyrrhizin
acid
glycyrrhizin
acid
isol
rhizom
glycyrrhiza
uralensi
e
sweeten
agent
sktk
exist
natur
glucuronid
conjug
acid
henc
make
substrat
bglumedi
hydrolysi
consequ
releas
activ
inhibitor
vitro
evalu
e
coli
rat
liver
bglu
reveal
stronger
potenc
glycyrrhizin
acid
ic
mm
respect
compar
acid
ic
fig
natur
bglu
inhibitor
profil
plant
extract
ethnomedicin
prepar
mm
respect
moreov
mgkg
dose
oral
treatment
glycyrrhizin
acid
intraperiton
treatment
acid
protect
hepatocyt
male
wistar
rat
ccl
induc
liver
injuri
evid
signific
reduct
ast
alt
ldh
level
compar
ccl
intraperiton
administr
glycyrrhizin
acid
also
provid
hepatoprotect
akin
tectoridin
addit
structur
similar
emodinol
isol
root
perenni
herb
paeonia
emodi
show
stronger
e
coli
bglu
inhibit
vitro
ic
mm
compar
acid
microbi
biotransform
drug
andor
precursor
new
molecul
modul
pharmacolog
profil
consid
invalu
tool
drug
design
develop
natur
product
class
e
steroid
key
substrat
regard
accordingli
natur
occur
androstan
steroid
hormon
fig
macrophomina
phaseolina
metabolit
examin
bglu
inhibitori
potenti
inferior
potencyinact
metabolit
compar
parent
ic
mm
suggest
alken
unit
cyclopentanon
unit
molecular
architectur
crucial
inhibitori
potenc
convers
synthet
anabol
steroid
dianabol
metabolit
filament
fungu
cunninghamella
elegan
macrophomina
phaseolina
inact
bglu
except
metabolit
ic
mm
eoxim
deriv
inact
metabolit
howev
show
decent
inhibitori
potenc
ic
mm
equipot
dsal
superior
zisom
nonetheless
therapeut
safeti
dianabol
deriv
bglu
inhibitor
question
consid
increas
risk
hepatotox
associ
oral
administr
anabol
steroid
fascin
abil
prebiot
probiot
posit
influenc
composit
behaviour
human
intestin
microbiota
continu
explor
consider
success
improv
human
health
precis
lactic
acid
bacteria
lab
probiot
select
util
nondigest
oligosaccharid
prebiot
carbon
sourc
produc
activ
metabolit
modul
stimul
activ
certain
intestin
bacteria
henc
elicit
import
physiolog
respons
confer
health
benefit
consequ
lab
e
lactobacillu
acidophilu
csg
afford
stronger
inhibit
intestin
bacteria
includ
e
coli
produc
bglu
thu
provid
hepatoprotect
male
icr
mice
compar
lactobacillu
brevi
bifidobacterium
iongum
anaerob
cocultur
e
coli
l
acidophilu
csg
also
potent
inhibit
bglu
product
e
coli
compar
lab
result
oral
treatment
murin
model
mgkg
l
acidophilu
csg
allevi
ccl
induc
hepatotox
lower
ast
alt
level
respect
ccl
control
group
wherea
tbhpinduc
hepatotox
ast
alt
level
lower
respect
better
refer
hepatoprotect
agent
ddb
similarli
lactobacillu
plantarum
cfr
effect
strain
lactobacilli
metabol
fructooligosaccharid
prebiot
short
chain
fatti
acid
therebi
alter
bglu
product
e
coli
lactic
acid
fig
especi
nbutyr
acid
identifi
major
short
chain
fatti
acid
metabolit
cultur
filtrat
lactobacillu
plantarum
cfr
fructooligosaccharid
respons
observ
decreas
bglu
activ
abund
rel
stabl
thiosulfin
smethyl
methanethiosulfin
fig
found
chines
chive
allium
tuberosum
rottier
exhibit
strong
inhibitori
potenc
ic
mm
e
coli
bglu
compar
disulphid
viz
dimethyl
allyl
methyl
diallyl
disulphid
compound
use
allevi
drug
induc
toxic
provid
hepatoprotect
parallel
natur
occur
acet
isol
red
macroalga
neodilsea
yendoana
isogloiosiphon
b
possess
similar
potenti
although
weaker
potenc
ic
mm
compar
compound
advers
role
inflammatori
pathway
correspond
mediat
includ
lysosom
enzym
pathogenesi
myocardi
infarct
implic
bglu
cardiovascular
diseas
studi
examin
protect
effect
thymol
fig
inflamm
isoproterenolinduc
myocardi
infarct
use
male
albino
wistar
rat
therapeut
benefit
inhibit
releas
bglu
lysosom
enzym
proinflammatori
cytokin
evid
restor
nearnorm
myocardi
histolog
function
compar
diseas
control
rat
pre
cotreat
thymol
intragastr
gavag
mgkg
bodi
weightday
day
subcutan
inject
mgkg
isoproterenol
day
day
show
significantli
reduc
level
cardiac
troponint
cardiotox
biomark
highsensit
creactiv
protein
sera
compar
treat
isoproterenol
importantli
activ
lysosom
enzym
ie
bglu
bgalactosidas
cathepsin
b
serum
heart
also
potent
inhibit
nearnorm
antiinflammatori
effect
thymol
afford
wellprotect
myocardium
stabl
histolog
architectur
polyhydroxyl
piperidin
pyrrolidin
alkaloid
commonli
refer
iminosugar
fig
nobl
class
sugar
mimic
pyrano
furano
endocycl
oxygen
replac
basic
nitrogen
atom
class
also
includ
isoiminosugar
ie
methylen
unit
place
endocycl
oxygen
anomer
carbon
replac
nitrogen
although
ring
alter
render
iminosugar
metabol
inert
proton
form
mimic
pyranosyl
furanosyl
unit
gh
substrat
especi
put
oxocarbenium
ionlik
transit
state
fig
gh
catalys
hydrolysi
turn
facilit
recogniz
gh
carbohydraterecogn
protein
correspond
enzym
inhibit
sinc
isol
nojirimycin
first
iminosugar
siastatin
b
first
isoiminosugar
streptomyc
cultur
respect
sugar
mimic
recur
subject
intens
research
owe
extens
biolog
activ
therapeut
applic
elicit
majorli
potent
inhibit
gh
strongest
iminosugarbas
inhibitor
bovin
liverderiv
bglu
report
far
fig
promis
antitumor
potenti
siastatin
b
deriv
ic
nm
respect
therefor
section
review
iminosugar
analogu
natur
productinspir
bglu
inhibitor
without
undu
repetit
monograph
cover
uron
analogu
nojirimycin
bear
bicycl
analogu
imidazol
tetrazol
unit
ie
respect
prepar
examin
effect
sugaracid
configur
presenc
lactam
tetrazol
imidazol
moieti
inhibitori
potenc
bovin
liver
bglu
evidenc
potent
inhibitor
fig
k
nm
glucoconfigur
unit
stronger
bglu
inhibitor
compar
galactoand
mannoanalogu
due
better
mimicri
glucuron
acid
imidazol
ring
also
confer
stronger
inhibitori
potenc
tetrazol
lactam
unit
wherea
glycarolactam
tetrazol
share
similar
potenc
except
galactotetrazol
inferior
potenc
galactolactam
although
sugar
configur
found
ineffect
bglu
inhibit
signific
tetrazol
imidazol
deriv
glucotetrazol
better
galactotetrazol
glucoimidazol
potent
galactoimidazol
superior
mannoimidazopyridin
differ
moreov
sugar
configur
acid
moieti
also
signific
influenc
potenc
lconfigur
unit
weaker
disom
respect
importantli
increas
potenc
glucoimidazol
compar
glucotetrazol
attribut
stronger
interact
glucoimidazol
catalyt
nucleophil
compar
glucotetrazol
interact
catalyt
acid
compromis
due
proton
imidazol
ring
zwitterion
form
convers
similar
bicycl
molecul
nojirimycin
cyclic
carbam
urea
guanidin
pharmacophor
weaker
bglu
inhibitor
cyclic
carbam
fig
show
moder
inhibitori
activ
bovin
liver
bglu
cyclic
carbam
carboxyl
acid
unit
nojirimycin
ring
also
better
inhibitor
hydroxymethyl
analogu
thu
compound
potent
overal
ic
mm
respect
noteworthi
bicycl
indolizidin
iminosugar
hydroxymethyl
unit
also
weak
inhibitor
inhibit
mm
although
exhibit
desir
select
e
coli
bglu
surprisingli
carbasugar
share
similar
fate
ic
mm
e
coli
bglu
even
though
iminosugar
taken
togeth
result
partli
suggest
abil
mimic
dglucuron
acid
favour
bglu
inhibitori
activ
accordingli
glucuron
acid
analogu
natur
occur
hemiamin
calystegin
b
fig
uronicnoeurostegin
synthes
levoglucosan
compound
confer
improv
select
e
coli
bglu
partli
due
improv
lipophil
balanc
bacteri
cell
penetr
afford
calkyl
unit
improv
chemic
stabil
cec
bond
pseudoanomer
centr
liminosugar
cglycosid
adenophorin
fig
enantiom
natur
iminosugar
cglycosid
adenophorin
prepar
togeth
analogu
via
skelet
rearrang
correspond
azepan
howev
compound
analogu
found
weak
select
inhibitor
e
coli
bglu
cpropyl
analogu
compound
ic
mm
show
total
select
bacteri
ortholog
also
superior
compound
azepan
precursor
iminosugar
studi
show
moder
select
inhibit
mm
howev
increas
lipophil
azepan
scaffold
via
nalkyl
tune
configur
alkyl
hydroxi
substitu
respect
fig
birth
e
coli
bglu
inhibitor
markedli
increas
potenc
highli
conserv
select
sar
analysi
reveal
combin
eoh
unit
nalkyl
hexyl
nonyl
dodecyl
produc
stronger
inhibitor
potenc
increas
increas
chain
length
contrast
cbutyl
cnonyl
deriv
compound
respect
activ
calkyl
analogu
ic
mm
respect
compound
stronger
nalkyl
analogu
compound
show
compromis
select
ic
mm
bovin
liver
bglu
overal
highli
lipophil
compound
endodecyl
framework
strongest
inhibitor
ic
mm
superior
potenc
e
nnonyl
analogu
ic
mm
absolut
select
e
coli
bglu
furthermor
substitu
type
configur
also
influenc
inhibitori
potenc
noeuromycin
azepan
analogu
configur
compound
weakli
potent
compar
inact
configur
analogu
compound
ic
mm
potent
analogu
compound
incorpor
acetamido
unit
siastatin
b
retain
iminosugar
cglycosid
scaffold
via
similar
skelet
rearrang
azepan
afford
lconfigur
cglycosid
weak
inhibitori
potenc
sugar
configur
fig
significantli
influenc
select
gh
henc
configur
molecul
select
inhibitor
e
coli
bglu
inact
bovin
liver
bglu
anacetylgalactosaminidas
bnacetylgalactosaminidas
wherea
configur
infus
select
bnacetylgalactosaminidas
consequ
configur
compound
rigid
benzyl
substitu
emerg
best
e
coli
bglu
inhibitor
seri
ic
mm
compar
inhibit
mm
compound
configur
butyl
unit
author
attribut
inferior
activ
stereochem
mismatch
lconfigur
unit
dconfigur
substrat
gh
also
conceiv
presenc
hydroxymethyl
carboxyl
unit
mimic
glucuron
acid
might
also
respons
weak
inhibitori
potenc
inde
case
acid
uron
analogu
disom
stronger
correspond
lisom
activ
bglu
inhibitor
better
mimicri
glucuron
acid
viz
dgluco
dgalacto
configur
unit
compound
respect
fig
compound
show
select
bovin
liver
bglu
ic
mm
wherea
compound
display
exclus
inhibit
ic
mm
azol
promin
class
heterocycl
least
one
nitrogen
atom
aromat
ring
due
structur
rigid
amaz
physicochem
properti
confer
highli
covet
broad
pharmacolog
activ
spectrum
therapeut
potenti
remain
target
scaffold
mani
synthet
protocol
member
class
includ
pyrazol
imidazol
thiazol
triazol
oxadiazol
thiadiazol
tetrazol
togeth
benzo
analogu
ie
indol
benzimidazol
benzothiazol
benzotriazol
compound
also
enjoy
increas
hydrogen
bond
hb
capabl
furnish
ring
n
andor
atom
biomolecular
target
bind
consequ
section
overview
report
bglu
inhibitor
bear
one
azol
nuclei
critic
focu
potent
inhibitor
given
seri
pharmacolog
profil
structureact
relationship
sar
molecular
dock
analysi
bglu
inhibitori
potenc
ic
mm
set
imidazolylethylaryl
carboxyl
compar
refer
inhibitor
dsal
ic
mm
compound
fig
emerg
potent
bglu
inhibitor
ic
mm
superior
potenc
dsal
sar
analysi
support
silico
studi
articul
compound
electrondon
group
edg
display
inferior
inhibitori
activ
compar
electronwithdraw
group
ewg
moreov
molecular
hybrid
indol
nucleu
result
potent
bglu
inhibitor
compound
ic
mm
increas
potenc
dsal
compound
display
strong
hb
interact
indol
nh
unit
pp
interact
activ
site
residu
bglu
vitro
screen
imidazolopyridin
fig
bglu
inhibitori
potenti
present
dihydroxysubstitut
deriv
promis
inhibitor
enzym
activ
fig
howev
replac
oh
unit
lipophil
meo
eto
group
led
signific
loss
activ
molecular
dock
analysi
also
disclos
import
imin
nitrogen
proxim
thiazol
nitrogen
catalyt
acid
strong
inhibitori
potenc
compound
adjac
oh
unit
favour
fit
bglu
catalyt
pocket
stronger
interact
amino
acid
residu
howev
instal
moieti
thiazol
skeleton
improv
bglu
inhibitori
potenc
com
br
meo
substitu
weaker
inhibitor
result
compound
ic
mm
fig
potent
inhibitor
stronger
compound
dsal
respect
dock
studi
reveal
free
amino
nh
unit
compound
form
strong
hb
interact
oh
unit
catalyt
acid
dichloro
substitu
also
substitut
phenyl
unit
benzimidazol
core
activ
depend
presenc
posit
cl
oh
substitu
henc
analogu
fig
found
strongest
inhibitori
potenc
ic
mm
interestingli
introduc
unit
benzimidazol
nucleu
gave
remark
result
previous
inact
molecul
gain
signific
activ
compound
emerg
potent
inhibitor
overal
ic
mm
stronger
dsal
moreov
replac
oh
unit
dihydroxi
substitu
meo
led
signific
total
loss
activ
f
naphthyl
anthracenyl
unit
also
gave
inact
compound
molecul
contain
ewg
cl
f
group
superior
seri
fig
thu
best
activ
found
ortho
akin
imidazoleindol
hybrid
compound
ic
mm
fig
molecular
hybrid
benzimidazol
amid
bond
bioisoster
result
isopot
hybrid
fig
ic
mm
ohsubstitut
deriv
stronger
inhibitor
compar
contain
f
cl
meo
substitu
dock
studi
reveal
molecular
hybrid
adopt
linear
configur
activ
site
bglu
oxadiazol
nucleu
centralphenyl
ring
compound
form
strong
hb
interact
nh
unit
phenol
oh
respect
compound
ic
mm
hand
interact
catalyt
acid
via
central
phenyl
phenol
ring
respect
anoth
compar
studi
use
lead
replac
benzimidazol
benzohydrazon
unit
fig
import
benzimidazol
nucleu
bglu
inhibitori
activ
establish
pronounc
loss
activ
nevertheless
ohsubstitut
deriv
benzenetriol
compound
emerg
strongest
inhibitor
ic
mm
inhibitori
potenc
depend
substitu
posit
order
para
meta
ortho
oh
cl
group
presenc
meo
group
gave
inact
compound
molecular
dock
studi
show
inhibitori
activ
correl
strongli
strength
hb
interact
henc
improv
potenc
seen
ohsubstitut
deriv
notabl
benzenetriol
oh
unit
compound
form
hb
interact
benzohydrazid
unit
interact
similarli
like
manner
replac
pharmacophor
compound
ie
hydroxyl
methoxi
imin
polar
sulfonamid
unit
fig
led
stronger
bglu
inhibitori
potenc
result
oxadiazolebenzenesulfonamid
potent
inhibitor
compound
ic
mm
respect
compound
show
similar
potenc
compound
inhibitori
activ
improv
parasubstitut
deriv
ewg
produc
stronger
inhibitor
edg
bind
interact
activ
site
bglu
especi
hb
interact
benzamid
nh
unit
establish
improv
activ
sulfonamid
compar
benzohydrazon
compound
form
hb
interact
via
sulfonyl
oxygen
benzamid
oxygen
interact
similar
fashion
addit
ionic
bond
group
compound
also
account
improv
potenc
molecular
hybrid
fig
inhibitor
dsal
respect
fig
silico
studi
benzothiazol
reveal
adopt
linear
conform
allow
appropri
fit
bind
groov
bglu
orthooh
unit
compound
form
strong
hb
interact
paraoh
unit
provid
hb
interact
enzymeinhibitor
complex
stabil
activ
site
hydrophob
interact
benzenetriol
ring
indol
nucleu
importantli
activ
inhibitor
noncytotox
cytotox
assay
use
mous
embryo
fibroblast
wistar
rat
hepatocyt
benzothiazol
benzimidazol
bioisoster
due
structur
pharmacolog
similar
therefor
bioisoster
replac
one
consist
explor
drug
develop
accordingli
bioisoster
replac
benzimidazol
moieti
compound
give
new
benzothiazoleoxadiazol
hybrid
result
equal
potent
bglu
inhibitor
potent
compound
fig
ic
mm
equipot
compound
fascinatingli
compound
ic
mm
also
isopot
similarli
substitut
compound
dock
studi
compound
show
hb
interact
phenol
oh
unit
activ
site
residu
viz
favour
strong
inhibitori
potenc
moreov
compound
form
hydrophob
interact
via
thiazol
core
benzen
ring
respect
reduc
potenc
compound
establish
strength
interact
well
absenc
addit
van
der
waal
contact
benzothiazol
ring
compound
catalyt
residu
silico
pharmacokinet
properti
model
inhibitor
predict
good
cell
permeabl
solubl
compound
also
noncytotox
cell
line
follow
similar
molecular
develop
strategi
lead
compound
new
benzothiazolehydrazon
hybrid
assembl
delet
fragment
compound
fig
compar
parent
compound
seri
new
hybrid
mark
reduct
potenc
recur
pattern
reduc
abolish
activ
also
persist
meo
substitu
nevertheless
compound
triazol
triazol
ring
also
afford
potent
bglu
inhibitor
vitro
evalu
base
present
isatincontain
compound
fig
strongest
inhibitor
ic
mm
superior
activ
dsal
cl
oh
substitu
orthoposit
also
gave
appreci
activ
wherea
meo
cumyl
aryl
deriv
inact
dock
simul
compound
activ
site
bglu
reveal
strong
hb
interact
isatin
nh
catalyt
residu
phenyl
ring
also
provid
panion
pp
interact
respect
van
der
waal
contact
stabil
inhibitorbglu
complex
howev
amid
bond
bioisoster
stronger
bglu
inhibitor
compar
isom
molecular
hybrid
carbazol
deliv
eight
compound
ic
mm
fig
compound
ic
mm
potent
hybrid
seri
stronger
dsal
tether
noncytotox
cell
indolebas
hybrid
librari
indol
analogu
contain
hydrazon
unit
compound
examin
bglu
inhibit
evinc
increas
potenc
indol
pharmacophor
deliv
stronger
bglu
inhibitor
compar
benzothiazol
oxadiazol
instanc
potent
inhibitor
ic
mm
fig
potent
dsal
stronger
similarli
substitut
oxadiazol
variant
compound
librari
compound
ic
mm
ic
mm
also
stronger
respect
correspond
oxadiazol
variant
moreov
substitut
ortho
paraposit
gave
stronger
inhibitor
compar
metaposit
potenc
monosubstitut
analogu
follow
order
f
oh
cl
pyridyl
meo
excel
potenc
compound
afford
strong
hb
interact
well
indol
benzohydrazon
nh
unit
form
hb
interact
wherea
ligandreceptor
complex
stabil
palkyl
interact
indol
ring
expectedli
reduc
activ
compound
seen
weaker
interact
activ
site
bglu
base
pharmacolog
signific
thiadiazol
pharmacophor
promis
inhibitori
activ
indol
hybrid
compound
hybrid
indolethiadiazol
assembl
new
class
bglu
inhibitor
gener
thiadiazol
nucleu
infus
stronger
inhibitori
potenc
result
hybrid
compar
hydrazon
unit
dihydroxi
substitut
compound
emerg
strongest
inhibitor
ic
mm
equipot
compound
orthosubstitut
benefici
potenc
para
metasubstitut
inhibitor
strength
follow
order
oh
f
pyridyl
cl
fig
howev
bioisoster
replac
attempt
oxadiazol
prove
thiadiazol
unit
prefer
stronger
inhibit
strongest
potenc
remain
substitut
deriv
ic
mm
although
deriv
outli
potenc
bazedoxifen
fig
novel
indolebas
inhibitor
manag
tripl
neg
breast
cancer
also
select
estrogen
receptor
modul
administ
codrug
conjug
estrogen
duave
estrogen
replac
therapi
prevent
postmenopaus
osteoporosi
albeit
high
ratio
circul
estrogen
metabolit
parent
estrogen
aid
bglu
deglucuronid
activ
gut
consid
risk
factor
postmenopaus
estrogen
receptor
posit
breast
cancer
accordingli
studi
therapeut
util
combin
drug
ovariectom
mous
model
show
signific
reduct
faecal
bglu
activ
without
alter
faecal
microbiota
divers
studi
articul
signific
bacteri
bglu
inhibit
improv
outcom
longterm
administ
estrogen
postmenopaus
women
breast
cancer
patient
consist
excel
inhibitori
potenc
indolebas
compound
librari
bisindol
fig
report
strong
bglu
inhibitor
import
di
hydroxi
substitut
potenc
promin
compound
emerg
activ
molecul
ic
mm
superior
dsal
silico
studi
suggest
hb
donoracceptor
potenti
oh
unit
compound
significantli
influenc
ligandreceptor
interact
orthooh
form
strong
hb
amino
acid
residu
paraoh
interact
similarli
arenearen
interact
indol
ring
also
aid
favour
bind
bglu
anoth
studi
compound
compound
ic
mm
strongest
inhibitor
bacteri
bglu
albeit
moder
cytotox
mous
fibroblast
presenc
nphenyl
substitut
thiosemicarbazid
unit
howev
introduc
mark
increas
bglu
inhibit
inhibitori
potenc
monosubstitut
analogu
follow
order
f
z
cf
cl
br
meo
orthosubstitut
produc
best
result
fig
accordingli
also
form
hb
interact
amid
nh
arenearen
interact
phenyl
ring
tolyl
unit
chalcon
class
natur
occur
flavonoid
famili
synthet
obtain
compound
extens
therapeut
applic
presenc
highli
reactiv
bunsatur
keton
unit
deloc
electron
make
covet
precursor
mani
synthet
manipul
pharmacolog
explor
proinflammatori
role
bglu
inflammatori
disord
motiv
design
seri
di
hydroxychalcon
fig
inhibit
releas
bglu
stimul
rat
mast
cell
neutrophil
establish
hydroxychalcon
stronger
select
inhibitor
neutrophilderiv
bglu
mast
cellderiv
bglu
best
inhibitor
compound
ic
mm
select
ic
mm
select
sar
analysi
showcas
import
b
compound
fig
emerg
potent
inhibitor
inhibit
mm
stronger
standard
salicyl
acid
amongst
seri
chalconemannich
adduct
adopt
similar
molecular
design
librari
chalconebenzamid
found
slightli
improv
potenc
sar
analysi
establish
prefer
ewg
edg
better
enzym
inhibit
compound
contain
similar
substitu
compound
emerg
potent
molecul
inhibit
mm
stronger
potenc
salicyl
acid
mm
also
noncytotox
assay
contrast
increas
cytotox
equal
potent
analogu
notabl
activ
modul
substitut
trimethoxi
unit
indol
unsuccess
lead
promin
reduct
percentag
inhibitori
activ
chalcon
structur
develop
coumarin
compound
fig
recov
virtual
screen
deliv
set
moder
potent
inhibitor
bglu
activ
superior
activ
compar
dsal
ic
mm
record
compound
ic
valu
mm
respect
anoth
attempt
despit
differ
molecular
tune
includ
polar
oh
cl
group
coumarin
pharmacophor
remain
inact
bacteri
bglu
convers
structur
isomer
flavenon
bear
pyranos
appendag
show
stronger
inhibit
bacteri
bglu
compound
fig
activ
inhibitor
thereof
ic
mm
superior
potenc
dsal
total
noncytotox
mous
fibroblast
silico
studi
disclos
import
pyranos
ring
hb
interact
activ
site
residu
fascinatingli
introduc
pharmacophor
scaffold
fig
led
signific
increas
potenc
new
hybrid
exhibit
consist
trend
potenc
base
substitu
type
posit
order
f
cl
pyridyl
meo
ortho
para
meta
respect
thu
hand
azacoumarin
basic
nitrogen
atom
place
endocycl
coumarin
oxygen
confer
stronger
select
inhibitori
potenc
bacteri
bglu
plausibl
admir
activ
provid
abil
mimic
interfer
oxocarbenium
ionlik
transit
state
akin
iminosugar
thu
allow
allevi
druginduc
toxic
prevent
colon
carcinoma
renown
exampl
class
bglu
inhibitor
strongli
potent
azacoumarin
fig
identifi
highthroughput
screen
compound
exhibit
vitro
ic
valu
mm
respect
select
e
coli
bglu
increas
potenc
refer
inhibitor
glucarodlactam
inhibitor
also
maintain
potenc
live
bacteri
cell
ec
mm
similarli
activ
compound
ic
daili
allevi
irinotecan
induc
diarrhoea
evid
protect
gi
epithelium
balbcj
mice
compar
bloodi
diarrhoea
due
damag
tissu
glandular
structur
receiv
alon
pretreat
mice
mg
inhibitor
intraperiton
administr
ulcerogen
dose
nsaid
e
diclofenac
mgkg
indomethacin
mgkg
ketoprofen
mgkg
also
success
protect
mice
model
nsaidinduc
small
intestin
mucos
damag
moreov
compound
reduc
enteropathi
paramet
inhibit
gi
bacteri
bglumedi
hydrolysi
nsaidacyl
glucuronid
concentrationdepend
manner
ic
z
mm
interestingli
compound
alter
drug
system
exposur
hepatobiliari
excret
glucuronid
gi
microbiota
divers
although
possess
short
halflif
h
pancytochrom
poor
bioavail
howev
attempt
reduc
inhibitor
serum
exposur
increas
gi
resid
replac
ethoxi
unit
hydroxyl
morpholinyl
group
led
inferior
pharmacolog
profil
compar
parent
compound
compound
exert
reduct
sever
diclofenacinduc
anastomot
leakag
without
affect
drug
plasma
concentr
wistar
rat
receiv
mg
inhibitor
mgkg
diclofenac
contrast
rat
receiv
diclofenac
suffer
sever
leakag
thu
suggest
inhibitor
potenti
clinic
util
improv
anastomot
heal
emerg
screen
protocol
birth
compound
three
piperazinecontain
compound
fig
show
promis
inhibitori
potenti
bacteri
bglu
though
slightli
weaker
inhibitori
strength
ic
therapeut
signific
fuse
pyridinonefuran
antiinflammatori
drug
candid
via
inhibit
neutrophilderiv
bglu
report
compound
bear
meo
cf
substitu
ring
b
fig
show
inhibit
mm
cytotox
effect
mm
assay
compar
refer
salicyl
acid
inhibit
replac
ring
b
furan
thiophen
pyridin
howev
gave
poor
inhibitor
inhibit
compound
potent
inhibit
inhibitori
potenc
dihydropyrimidinon
carboxyl
fig
bovin
liverderiv
bglu
reiter
small
polar
substitu
necessari
strong
enzym
inhibit
appreci
potenc
ic
mm
exclus
cf
f
oh
thienyl
cl
substitut
compound
order
wherea
meo
br
benzyloxi
furanyl
aliphat
alkyl
aryl
unit
either
reduc
potenc
cosubstitut
polar
f
oh
group
gave
inferior
activ
monosubstitut
render
molecul
total
inact
therefor
activ
compound
ic
mm
found
favour
fit
activ
site
bglu
form
strong
hb
interact
key
residu
nh
hb
donor
acceptor
pyrimidinon
carbonyl
oxygen
free
nh
respect
carboxyl
carbonyl
oxygen
interact
similarli
wherea
nh
interact
catalyt
residu
howev
pyrimidinetrion
barbitur
acid
exhibit
inferior
potenc
compar
standard
dsal
ic
mm
despit
similar
bind
interact
compound
activ
site
residu
noncytotox
cell
predat
studi
structur
homolog
pyrimidinon
quinazolinon
exhibit
uniqu
trend
inhibitori
potenc
ecoli
bglu
signific
toler
lipophil
alkoxi
group
although
poor
activ
methyl
substitu
persist
activ
compound
fig
intriguingli
replac
alkoxi
unit
polar
oh
cl
substitu
led
signific
reduct
potenc
inhibitori
potenc
therefor
follow
order
meo
eto
n
oh
cl
ortho
para
meta
importantli
quinazolinonebas
inhibitor
noncytotox
cell
also
noteworthi
quinazolinon
compound
tabl
si
ref
also
show
strong
inhibitori
potenc
ic
mm
bacteri
bglu
quinolin
nucleu
regard
household
name
medicin
chemistri
due
inexhaust
pharmacolog
applic
occurr
mani
clinic
import
natur
product
synthet
molecul
desir
pharmacokinet
profil
eas
access
wide
substrat
toler
differ
synthet
protocol
also
encourag
util
countless
synthet
explor
research
endeavour
aim
quinolinebas
bglu
inhibitor
therefor
present
section
prepar
analog
hydrazon
tether
also
hold
promis
inhibitori
activ
similarli
oh
unit
orthoposit
yield
stronger
inhibitor
f
cl
pyridyl
thiophenyl
furanyl
z
meo
order
moreov
orthosubstitut
consist
gave
superior
inhibitor
compar
paraposit
metasubstitut
confer
weakest
potenc
reduct
potenc
persist
oh
unit
substitut
meo
unit
fig
henc
compound
ic
mm
ic
mm
emerg
potent
inhibitor
overal
dock
studi
reveal
oh
unit
quinolin
ring
foster
import
hb
interact
catalyt
acid
carbonyl
unit
hydrazon
moieti
form
hb
interact
nh
anoth
quest
new
antiinflammatori
agent
quinolinefuran
hybrid
fig
design
inhibitor
bglu
releas
activ
neutrophil
sar
analysi
establish
quinolin
type
stronger
inhibitor
inflammatori
mediat
tricycl
furo
quinolin
type
b
wherea
formyl
unit
favour
potenc
compar
acetyl
oxim
methyl
oxim
well
bunsatur
satur
variant
therefor
noncytotox
compound
ic
mm
strongest
inhibitor
bglu
releas
superior
refer
trifluoperazin
acetyl
isom
compound
also
similar
noncytotox
strong
inhibitori
potenc
ic
mm
akin
azacoumarin
new
quinolinepyrazol
conjug
prepar
via
hit
develop
protocol
compound
fig
identifi
highthroughput
screen
inhibit
intestin
bacteri
bglu
hydrolyt
activ
fo
allevi
druginduc
toxic
interestingli
result
deriv
show
good
select
e
coli
bglu
except
substitut
deriv
trend
inhibitori
potenc
base
substitu
posit
vari
order
meta
ortho
para
presenc
strongli
hydrophil
oh
nh
unit
paraposit
detriment
potenc
follow
oral
administr
balbcj
mice
consecut
day
compar
compound
wherea
pharmacokinet
profil
compound
reveal
lower
plasma
concentr
increas
gi
resid
improv
intestin
bglu
inhibit
compar
azacoumarin
compound
importantli
oral
coadministr
compound
mg
kg
day
consecut
day
mg
kg
day
intraperiton
inject
protect
balbcj
mice
model
druginduc
intestin
mucos
injuri
without
alter
drug
therapeut
efficaci
furthermor
mechanist
studi
establish
presenc
electroneg
electroneutr
surfac
charg
e
coli
activ
site
pocket
proton
atom
avail
phdepend
select
inhibit
compound
fig
consequ
compound
clinic
viabl
agent
protect
gi
e
coli
bglumedi
mucos
damag
prevent
releas
chemic
carcinogen
crucial
develop
precancer
lesion
colon
carcinogenesi
increas
inhibitori
potenc
benzohydrazideencyanoethyl
tether
compar
parent
compound
articul
signific
balanc
molecular
lipophil
bglu
inhibit
oalkyl
benzyl
benzoyl
tosyl
group
slightli
influenc
potenc
ohsubstitut
unit
benzyl
produc
best
result
fig
henc
ic
mm
ic
mm
activ
conjug
seri
similarli
phenoxyacetohydrazon
display
improv
potenc
compar
dsal
ic
mm
compound
fig
emerg
desir
therapeut
signific
fuse
thienothiophen
stimul
synthet
explor
thienothiophen
skeleton
fig
bacteri
bglu
inhibit
result
thienothiophen
librari
interest
structur
divers
compound
show
inhibitori
activ
bacteri
bglu
ic
valu
mm
superior
potenc
dsal
notabl
predict
pharmacokinet
properti
use
molinspir
osiri
calcul
suggest
inhibitor
possess
good
bioavail
toxic
risk
bacteri
bglu
inhibitor
vitro
studi
phenyl
disulphideebenzenesulfonamid
tether
disclos
compound
fig
potent
inhibitor
bglu
ic
mm
respect
analog
similarli
substitut
oxadiazolebenzenesulfonamid
compound
fig
interestingli
bulkier
phenyl
disulfid
share
similar
potenc
lower
molecular
mass
thiosulfin
fig
ic
mm
howev
substitut
orthoposit
gave
stronger
inhibitor
paraand
metaposit
contrast
compound
seri
dock
studi
reveal
strong
inhibitori
potenc
compound
aid
hb
interact
sulfonamid
nh
oxygen
respect
efficaci
urea
unit
bglu
inhibit
also
examin
use
librari
substitut
nphenyl
urea
therefrom
appropri
posit
polar
unit
import
inhibitori
potenc
examin
molecul
compound
fig
emerg
inhibitor
promis
activ
ic
valu
mm
howev
thiourea
analogu
bear
metacl
substitu
nphenyl
ring
stronger
inhibitor
compar
unsubstitut
nphenyl
ring
substitut
urea
fig
akin
compound
thiourea
contain
piperazin
unit
also
exhibit
improv
potenc
compar
morpholin
piperidin
analogu
nalkyl
piperazin
n
pmethoxyphenyl
n
extant
empir
data
identifi
bacteri
bglu
chelat
agent
sinc
enzym
activ
total
lost
presenc
cu
hg
ag
metal
ion
restor
presenc
chelat
agent
e
versen
cystein
therefor
metal
complex
coordinat
metal
centr
exhibit
signific
bacteri
bglu
inhibitori
activ
end
pd
ii
complex
contain
anilin
triphenylphosphin
ligand
synthes
parachloroanilin
deriv
metal
complex
fig
display
strongest
activ
bacteri
bglu
inhibit
ic
mm
also
superior
metachloroanilin
deriv
nmethyl
substitut
metal
complex
respect
similarli
nheterocycl
carben
nhc
complex
au
well
bi
nhc
complex
au
au
iii
contain
hydroxi
chlorid
acetoxi
acetonyl
ligand
equal
potent
bacteri
bglu
inhibitor
ic
rang
mm
strongest
au
nhc
complex
ic
mm
potent
refer
dsal
superior
strongest
bi
nhc
complex
nonetheless
undesir
cytotox
cell
discomfit
therapeut
signific
metal
complex
parallel
iminosugar
inhibitori
potenc
structur
similar
glycopolym
fig
depend
presenc
carboxyl
unit
type
configur
sugar
unit
henc
glycopolym
dglucar
pendant
link
polym
frame
stronger
inhibitor
compar
glycopolym
link
bear
dglucon
dmannar
shorter
chain
lxylar
ltartar
pendant
howev
glycopolym
show
inhibit
millimolar
concentr
patent
patent
applic
disclos
potent
inhibit
bglu
particularli
bacteri
bglu
therapeut
signific
thereof
document
therefor
review
section
patent
applic
file
present
millennium
relev
bglu
inhibit
also
includ
biomark
applic
enzym
file
within
period
howev
patent
applic
eman
publish
paper
review
previou
section
therefor
summari
present
tabl
consid
limit
associ
tradit
clinic
assess
periodont
diseas
diagnosi
improv
reliabl
bglu
biomark
simpl
method
requir
less
expertis
claim
quantifi
elev
level
enzym
saliva
diseas
patient
rel
healthi
one
biomark
diseas
risk
statu
invent
involv
ad
known
bdglucuronid
substrat
phenolphthalein
bdglucuronid
sampl
patient
saliva
bglu
activ
assay
thereaft
quantifi
amount
aglycon
produc
via
fluorometri
colorimetri
spectrophotometri
addit
label
polyclon
monoclon
antibodi
specif
bglu
saliva
sampl
subsequ
estim
amount
label
antibodi
form
bgluantibodi
complex
also
claim
well
testkit
claim
method
bacteri
bglumedi
hydrolysi
steroid
glucuronid
skin
lead
bodi
odour
henc
inhibitor
process
develop
appli
deodor
antiperspir
formul
invent
claim
deodor
formul
describ
compound
inhibit
bglu
activ
without
alter
natur
composit
skin
microbiota
contrast
bacteriostat
bactericid
mode
action
prior
art
amongst
claim
inhibitor
differ
class
strongest
inhibit
e
coli
bglu
found
galactar
acid
inhibit
test
concentr
water
well
zinc
glycin
zinc
glucon
inhibit
respect
test
concentr
vein
potent
inhibitor
bacteri
bglu
activ
urin
found
nontherapeut
applic
hygien
sanitari
product
suppress
gener
urin
odour
wt
dipropylen
glycol
claim
inhibitor
viz
macrocycl
keton
keton
macrocycl
lacton
macrocycl
oxalacton
ester
aldehyd
alcohol
ether
terpen
show
inhibit
e
coli
bglu
macrocycl
keton
stronger
inhibitor
other
consequ
invent
activ
inhibitor
compound
inhibit
wt
respect
also
effect
h
suppress
increas
urin
odour
incorpor
differ
hygien
sanitari
product
phenoxi
thiophen
sulfonamid
design
adjuv
elimin
doselimit
gi
toxic
diarrhoea
potent
inhibit
bacteri
bglumedi
deconjug
activ
metabolit
glucuronid
intestin
thu
improv
drug
therapeut
efficaci
synthesi
bglu
inhibitor
analogu
compound
activ
compound
ic
nm
togeth
therapeut
applic
claim
sar
studi
compound
analogu
reveal
inhibitori
potenc
markedli
depend
npiperazinyl
pendant
metaposit
phenoxi
ring
reduc
inhibitori
potenc
occur
nmethyl
akin
compound
reduct
append
paraposit
total
loss
activ
remov
uninstal
chloro
unit
thiophen
ring
also
slightli
diminish
potenc
wherea
replac
naphthyl
substitut
phenyl
unit
afford
inhibitor
similar
potenc
ie
ic
nm
tabl
si
result
equipot
bglu
physiolog
import
lysosom
glycosyl
hydrolas
appreci
therapeut
potenti
biomark
diseas
diagnosi
endogen
bioactiv
prodrug
monotherapi
enzym
replac
therapi
enzym
role
cell
prolifer
inflamm
also
render
potenti
target
anticanc
antiinflammatori
drug
develop
respect
moreov
sinc
signific
number
commerci
avail
drug
metabolis
glucuronid
hydrolyt
activ
ie
deglucuronid
bglu
human
intestin
microbiota
link
colon
carcinogenesi
genotox
well
druginduc
doselimit
toxic
anticanc
agent
nsaid
thwart
therapeut
potenti
clinic
util
therefor
potent
inhibit
bglu
hold
enorm
clinic
import
gener
literatur
survey
found
signific
number
natur
productsderiv
inhibitor
display
moder
inhibit
bglu
increas
potenc
found
inhibitor
contain
flavonoid
skeleton
physiolog
toler
accept
toxic
favour
pharmacodynam
profil
natur
inhibitor
posit
worthi
scaffold
warrant
witti
molecular
develop
addit
iminosugar
distinguish
uniqu
class
natur
productinspir
molecul
promis
potenti
regardless
usual
multipl
synthet
step
notabl
amongst
nojirimycin
analogu
iminosugar
cglycosid
confer
highli
select
inhibit
bacteri
bglu
howev
inhibitori
potenc
carbohydr
mimic
reli
sever
factor
sugar
configur
mimicri
glucuron
acid
substrat
correct
lipophil
balanc
henc
har
remark
potenti
ingeni
manipul
synthet
medicin
chemist
interest
explor
chemic
space
expressli
requir
hand
pure
synthet
inhibitor
show
fascin
divers
inhibitori
potenc
pattern
due
plethora
pharmacophor
enrich
possibl
singl
molecular
design
base
forego
comprehens
list
potent
synthet
inhibitor
ic
mm
review
provid
tabl
si
support
inform
evinc
nanomolar
ic
valu
quinolinepyrazol
piperazinecontain
compound
analogu
well
indol
nucleu
confer
strongest
inhibit
bglu
activ
overal
order
potenc
hydrazon
tether
found
bisindol
indol
quinolin
thiazol
benzothiazol
z
oxadiazol
wherea
cl
particularli
f
oh
substitu
orthoor
paraposit
usual
produc
stronger
bglu
inhibitor
compar
metasubstitut
taken
togeth
suggest
presenc
polar
group
strong
hydrogen
bond
potenti
crucial
inhibitori
potenc
indiscrimin
increas
molecular
lipophil
detriment
strong
bglu
inhibit
consequ
envisag
model
bglu
inhibitor
apposit
tune
lipophil
polar
easi
cell
penetr
favour
fit
bindingcatalyt
pocket
bglu
energet
stabl
bind
strong
enzym
inhibit
also
perceiv
rational
molecular
hybrid
activ
class
natur
product
synthet
molecul
furnish
stronger
inhibitor
bglu
improv
select
accept
toxic
profil
furthermor
found
due
mixtur
electroneutr
electroneg
spot
surfac
bacteri
bglu
bind
pocket
physiolog
ph
contrast
electroposit
spot
human
bglu
presenc
protonat
natom
confer
improv
select
bacteri
bglu
inhibit
particularli
true
piperazin
base
inhibitor
therefor
believ
probe
phenomenon
allow
structureact
guid
molecular
tune
afford
stronger
bglu
inhibitor
best
knowledg
mechanist
studi
behaviour
inhibitor
scanti
literatur
found
two
articl
describ
glucoimidazol
piperazin
base
inhibitor
investig
approach
provid
insight
behaviour
inhibitor
catalyt
cycl
bglu
therebi
allow
deeper
understand
import
structur
featur
crucial
inhibitori
activ
beyond
sar
molecular
dock
studi
final
hope
review
inspir
medicin
chemist
direct
search
light
toward
molecular
target
develop
new
therapeut
agent
improv
efficaci
better
human
health
consequenti
author
declar
conflict
interest
